Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV

Jeromie Ballreich; Timothy Levengood; Rena M. Conti

doi:10.1017/jme.2022.33

Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV

Jeromie Ballreich, Timothy Levengood, Rena M. Conti

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.

Original language	English (US)
Pages (from-to)	32-39
Number of pages	8
Journal	Journal of Law, Medicine and Ethics
Volume	50
Issue number	S1
DOIs	https://doi.org/10.1017/jme.2022.33
State	Published - 2022

Keywords

Drug Policy
Drug Pricing
HIV
PrEP

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1017/jme.2022.33

Cite this

@article{89f1c82e56034d56914704b72bd4c8ec,

title = "Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV",

abstract = "Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.",

keywords = "Drug Policy, Drug Pricing, HIV, PrEP",

author = "Jeromie Ballreich and Timothy Levengood and Conti, {Rena M.}",

year = "2022",

doi = "10.1017/jme.2022.33",

language = "English (US)",

volume = "50",

pages = "32--39",

journal = "Journal of Law, Medicine and Ethics",

issn = "1073-1105",

number = "S1",

}

TY - JOUR

T1 - Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV

AU - Ballreich, Jeromie

AU - Levengood, Timothy

AU - Conti, Rena M.

PY - 2022

Y1 - 2022

N2 - Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.

AB - Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.

KW - Drug Policy

KW - Drug Pricing

KW - HIV

KW - PrEP

UR - http://www.scopus.com/inward/record.url?scp=85135419113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135419113&partnerID=8YFLogxK

U2 - 10.1017/jme.2022.33

DO - 10.1017/jme.2022.33

M3 - Article

C2 - 35902088

AN - SCOPUS:85135419113

SN - 1073-1105

VL - 50

SP - 32

EP - 39

JO - Journal of Law, Medicine and Ethics

JF - Journal of Law, Medicine and Ethics

IS - S1

ER -

Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this